GlassScriptPhysician profile
Laura L Champagne
NPI 1992758684
$11,111.98
in general payments reported to CMS, 2019-2025
32 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $911 · 2020: $866 · 2021: $974 · 2022: $1,540 · 2023: $3,147 · 2024: $1,680 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,298 · Debt Forgiveness: $1,378 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,298.39 |
| Debt Forgiveness | $1,377.50 |
| Education | $145.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,129.37 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neuronetics, INC. | $1,437.31 | 2019-2023 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $863.79 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $639.20 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $613.34 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $611.57 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Abbvie INC. | $556.95 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $492.73 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $411.25 | 2020-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $404.85 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $387.21 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $366.35 | 2022-2025 | Auvelity |
| Alkermes, INC. | $359.95 | 2021-2025 | Lybalvi, Aristada |
| Tris Pharma INC | $336.12 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $268.12 | 2019-2024 | Hetlioz, Fanapt |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $227.59 | 2019-2025 | Aplenzin |
| Allergan, INC. | $186.71 | 2019-2020 | |
| Corium, LLC | $125.72 | 2022-2023 | Azstarys |
| Eisai INC. | $105.74 | 2020-2024 | |
| Neos Therapeutics, LP | $91.70 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $91.12 | 2021-2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $74.56 | 2023-2024 | Quviviq |
| Jazz Pharmaceuticals INC. | $50.92 | 2021-2022 | |
| Adlon Therapeutics L.P. | $42.86 | 2020-2021 | |
| Biogen, INC. | $42.06 | 2024 | |
| Owp Pharmaceuticals, INC. | $40.69 | 2019-2022 | |
| Tempus Ai, INC | $32.56 | 2024 | Tempus Pixel |
| Ironshore Pharmaceuticals INC. | $30.54 | 2019-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $28.29 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $23.44 | 2019 | |
| Shire North American Group INC | $20.84 | 2019 | |
| Noven Therapeutics, LLC | $18.53 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Champagne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.